An Icelandic biotechnology company on Wednesday will begin offering a new genetic test to assess a woman's risk for the most common forms of breast cancer, reigniting concern about the proliferation of unregulated genetic tests, the Washington Post reports. FDA does not regulate screening tests when they are conducted by the labs that offer them. According to the Post, laboratories currently are offering genetic testing for more than 1,200 conditions. The $1,625 breast cancer risk assessment -- created by deCODE Genetics, of Reykjavik, Iceland -- uses a blood sample or cheek swab to examine seven genetic variations found in studies by the company and others to be associated with an increased risk for breast cancer. Patients receive results allowing them to assess their risk for common forms of breast cancer. Studies indicate...
[read full story]
Your Web Site
